STATEMENT - July 29, 2022
Effective October 13, 2022, Dana-Farber Cancer Institute President and CEO, Laurie H. Glimcher, MD will conclude a five-year tenure as a member of the Board of Directors for GSK, the London-based company announced today.
Dr. Glimcher, who joined the pharmaceutical and biotechnology company as a Director in 2017, will continue her leadership of Dana-Farber Cancer Institute.
“I’m very proud of my service on the GSK Board as an advocate for patients with cancer and advanced cancer research,” said Glimcher. “I remain focused on reducing the burden of cancer here and around the world. This means ensuring expert, compassionate, and equitable care for all patients and advancing new treatments and cures.”
She will continue serving on the Board of Directors for Analog Devices, a Wilmington-based high performance device maker.
Media Contacts
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.